| The Innate Immune System and Inflammatory Bowel Disease (NCT00516776) | Norwegian University of Science and Technology | 2007-06-01 |
| High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children (NCT00495521) | Jacobus Pharmaceutical | 2007-06-01 |
| A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (NCT00606346) | Janssen Biotech, Inc. | 2007-05-31 |
| An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy (NCT00467922) | Corewell Health West | 2007-05-01 |
| Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine (NCT01083680) | AbbVie (prior sponsor, Abbott) | 2007-05-01 |
| General Surgical Outcomes Quality Improvement Database (UH-SOCRATES) (NCT00622557) | University Hospitals Cleveland Medical Center | 2007-05-01 |
| Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab (NCT00307931) | UCB Pharma | 2007-04-01 |
| Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease (NCT00409682) | Abbott | 2007-04-01 |
| Surveillance of Humira Injection in Korean Patients (NCT01083121) | AbbVie (prior sponsor, Abbott) | 2007-04-01 |
| Retrospective Data Analysis in Crohn's Disease (NCT01363427) | Ferring Pharmaceuticals | 2007-03-01 |
| Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft (NCT00610207) | Cook Group Incorporated | 2007-03-01 |
| Centocor Microarray Study of Patients (NCT00462072) | University of Rochester | 2007-03-01 |
| Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy (NCT00492791) | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 2007-03-01 |
| A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease (NCT00445432) | Abbott | 2007-03-01 |
| A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease (NCT00445939) | Abbott | 2007-02-01 |
| Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption (NCT00427804) | Atlanta VA Medical Center | 2007-01-01 |
| High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease (NCT00417690) | Jacobus Pharmaceutical | 2007-01-01 |
| Development of Workshop for Lifestyle Changing for Crohn's Disease Patients and Its Affect on the Disease's Indexes (NCT00376649) | Hadassah Medical Organization | 2007-01-01 |
| Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease (NCT00356408) | UCB Pharma | 2007-01-01 |
| Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS) (NCT00427921) | Abbott | 2007-01-01 |
| Pregnancy Exposure Registry for Tysabri® (NCT00472992) | Biogen | 2007-01-01 |
| Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease (NCT00409617) | Abbott | 2006-12-01 |
| Phase II Study of RR110 in Patients With Active Crohn's Disease (NCT00417391) | R&R Inc. | 2006-12-01 |
| A Study of Abatacept in Patients With Active Crohn's Disease (NCT00406653) | Bristol-Myers Squibb | 2006-12-01 |
| Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (NCT00349752) | UCB Pharma | 2006-11-01 |
| Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (NCT00333788) | UCB Pharma | 2006-10-01 |
| Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease (NCT00573469) | AstraZeneca | 2006-10-01 |
| Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease (NCT00353756) | Avidia | 2006-09-01 |
| Dietary Treatment of Crohn's Disease (NCT00343642) | Rush University Medical Center | 2006-09-01 |
| The Effects of Naltrexone on Active Crohn's Disease (NCT00663117) | Milton S. Hershey Medical Center | 2006-09-01 |
| Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560) (NCT00723840) | Merck Sharp & Dohme LLC | 2006-09-01 |
| Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI) (NCT00360022) | Vanderbilt University Medical Center | 2006-08-01 |
| Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon (NCT00348283) | Abbott | 2006-08-01 |
| Synbiotic Treatment in Crohn's Disease Patients (NCT00305409) | University of Dundee | 2006-06-01 |
| Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE) (NCT00338650) | Abbott | 2006-06-01 |
| Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668) (NCT00329420) | UCB Pharma | 2006-05-01 |
| Study of Antibiotics in the Treatment of Colonic Crohn's Disease (NCT00257699) | Mount Sinai Hospital, Canada | 2006-05-01 |
| Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab (NCT00308581) | UCB Pharma | 2006-04-01 |
| Phase II Study of HMPL-004 in Subjects With Crohn's Disease (NCT00655733) | Hutchison Medipharma Limited | 2006-04-01 |
| Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease (NCT00294112) | Mesoblast, Inc. | 2006-03-13 |
| Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease (NCT00291668) | UCB Pharma | 2006-03-02 |
| A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease (NCT00306215) | Amgen | 2006-03-01 |
| Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) (NCT00727298) | Merck Sharp & Dohme LLC | 2006-02-01 |
| Use of Oral Probiotics to Reduce Urinary Oxalate Excretion (NCT00587041) | Mayo Clinic | 2006-02-01 |
| Mucosal Healing Study in Crohn's Disease (CD) (NCT00297648) | UCB Pharma | 2006-02-01 |
| Protein and Energy Metabolism in Pediatric Crohn's Disease (NCT00583232) | Indiana University | 2006-02-01 |
| Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease (NCT00586352) | Indiana University | 2006-01-01 |
| Chromoendoscopy for Ulcerative Colitis Surveillance (NCT00274209) | Indiana University | 2005-12-01 |
| The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease (NCT00250198) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-11-03 |
| Effect of Glutamine on Intestinal Permeability in Crohn's Disease (NCT00838149) | All India Institute of Medical Sciences | 2005-11-01 |
| Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease (NCT00234741) | Synta Pharmaceuticals Corp. | 2005-11-01 |
| Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis (NCT00265772) | Hôpital Necker-Enfants Malades | 2005-11-01 |
| A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease (NCT00225810) | Ferring Pharmaceuticals | 2005-10-01 |
| Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease (NCT00130390) | Romark Laboratories L.C. | 2005-08-01 |
| Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease (NCT00138840) | Synta Pharmaceuticals Corp. | 2005-08-01 |
| Early Immunosuppressants in Crohn's Disease (NCT00546546) | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 2005-07-01 |
| Imuran Dosing in Crohn's Disease Study (NCT00113503) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2005-07-01 |
| The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels (NCT00167882) | Amsterdam UMC, location VUmc | 2005-07-01 |
| Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease (NCT00178438) | University of Rochester | 2005-06-01 |
| Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease (NCT00509639) | S.L.A. Pharma AG | 2005-05-01 |
| Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease (NCT00222378) | University of Miami | 2005-04-01 |
| Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease (NCT00098111) | Massachusetts General Hospital | 2005-04-01 |
| Trial of Growth Hormone Therapy in Pediatric Crohn's Disease (NCT00109473) | Children's Hospital Medical Center, Cincinnati | 2005-04-01 |
| Crohn's Disease Stem Cell Transplantation (NCT00271947) | Northwestern University | 2005-04-01 |
| Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease (NCT00267709) | Facet Biotech | 2005-02-01 |
| Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery (NCT00688636) | University of Pittsburgh | 2005-01-01 |
| Study for the Treatment of Crohn's Disease With Adacolumn (NCT00162942) | Otsuka America Pharmaceutical | 2005-01-01 |
| An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease (NCT00106314) | Inflabloc Pharmaceuticals | 2005-01-01 |
| Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED) (NCT00724958) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study (NCT00599625) | University of Virginia | 2004-10-01 |
| Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease (NCT00105300) | Abbott | 2004-10-01 |
| Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease (NCT00101946) | GlaxoSmithKline | 2004-10-01 |
| Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD) (NCT00300118) | Dr. Falk Pharma GmbH | 2004-09-01 |
| Zoledronate for Osteopenia in Pediatric Crohn's (NCT00798473) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2004-09-01 |
| Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease (NCT00195715) | Abbott | 2004-09-01 |
| Infectious Agents in Pediatric Crohn's (NCT00237055) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2004-08-01 |
| A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (NCT00160524) | UCB Pharma SA | 2004-07-01 |
| Study Evaluating ERB-041 in Active Crohn's Disease (NCT00245947) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-04-01 |
| A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease (NCT00078611) | Biogen | 2004-03-01 |
| Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 (NCT00308438) | Shire | 2004-03-01 |
| The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists (NCT00224562) | Assistance Publique - Hôpitaux de Paris | 2004-02-01 |
| A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (NCT00160706) | UCB Pharma SA | 2004-02-01 |
| Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease (NCT01698970) | Danone Global Research & Innovation Center | 2004-02-01 |
| Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870). (NCT00152425) | UCB Pharma | 2004-02-01 |
| STA-5326 in Crohn's Disease Patients (NCT00088062) | Synta Pharmaceuticals Corp. | 2004-02-01 |
| Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease (NCT00114803) | Boston Children's Hospital | 2004-01-01 |
| Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease (NCT00588653) | Mayo Clinic | 2004-01-01 |
| Safety of Celecoxib in Patients With Crohn's Disease (NCT00177866) | University of Pittsburgh | 2003-12-01 |
| A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease. (NCT00175292) | University of Alberta | 2003-12-01 |
| A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo) (NCT00152490) | UCB Pharma | 2003-12-01 |
| Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease (NCT00072839) | Shire | 2003-11-12 |
| Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732) (NCT00796250) | Merck Sharp & Dohme LLC | 2003-11-01 |
| Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial (NCT00723047) | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 2003-11-01 |
| OTIS Humira Pregnancy Registry (NCT01086059) | University of California, San Diego | 2003-11-01 |
| Evaluation of Urinary Isoprostanes in the Assessment of Children With Inflammatory Bowel Disease (NCT00215020) | Boston Children's Hospital | 2003-09-01 |
| Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) (NCT00705614) | Merck Sharp & Dohme LLC | 2003-07-01 |
| Extension Study of Semapimod 60 mg IV x 3 Days (NCT00741910) | Ferring Pharmaceuticals | 2003-07-01 |
| Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease (NCT00077779) | Abbott | 2003-07-01 |
| Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients (NCT00138879) | St Mark's Hospital Foundation | 2003-05-01 |
| Quality of Life in Pediatric Inflammatory Bowel Disease (NCT00061737) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2003-01-01 |